ARA-290
Also known as: ARA290, cibinetide, erythropoietin mimetic peptide, EPO derivative
Non-erythropoietic EPO mimetic studied for tissue protection and neuropathic pain.
Quick Reference
ARA-290 - Research Images
PSO vial render · Scientific images from Wikipedia · Tap to enlarge
Overview
Erythropoietin receptor agonist
Cibinetide is an erythropoietin receptor agonist which is under development for the treatment of a variety of different medical conditions. It was under development for the treatment of depressive disorders, but development for this indication was discontinued. The drug is under development by Araim Pharmaceuticals. Modified derivatives with a longer duration of action have also been developed.
Mechanism of Action
Cibinetide is an erythropoietin receptor agonist which is under development for the treatment of a variety of different medical conditions. It was under development for the treatment of depressive disorders, but development for this indication was discontinued. The drug is under development by Araim Pharmaceuticals. Modified derivatives with a longer duration of action have also been developed.
What Researchers Are Saying
Community Reports - Not Medical Advice
The following is aggregated from public forums, Reddit, and research communities. These are anecdotal reports from researchers only - not verified clinical data and not a recommendation of any kind.
ARA-290 (also known as ARA290, cibinetide) is studied within the tissue repair and recovery research community. Non-erythropoietic EPO mimetic studied for tissue protection and neuropathic pain.
Last updated October 28, 2026
Research status: emerging. ARA-290 appears across tissue repair and recovery research forums and academic literature. Researchers note this compound falls in the tissue repair category.
Last updated October 28, 2026
What Do You Think of This Peptide?
Share your opinion or research experience with ARA-290. Comments are reviewed before appearing.